Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian origin.
- 1 June 2003
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 89 (3) , 486-493
- https://doi.org/10.1016/s0090-8258(03)00138-0
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Phase II Trial of Weekly Single-Agent Paclitaxel in Platinum/Paclitaxel-Refractory Ovarian CancerJournal of Clinical Oncology, 2002
- Phase II Feasibility Study of Sequential Couplets of Cisplatin/Topotecan Followed by Paclitaxel/Cisplatin as Primary Treatment for Advanced Epithelial Ovarian Cancer: A National Cancer Institute of Canada Clinical Trials Group StudyJournal of Clinical Oncology, 2000
- Docetaxel for Patients With Paclitaxel-Resistant Müllerian CarcinomaJournal of Clinical Oncology, 2000
- Phase I Trial of Carboplatin, Paclitaxel, Etoposide, and Cyclophosphamide with Granulocyte Colony Stimulating Factor as First-Line Therapy for Patients with Advanced Epithelial Ovarian CancerGynecologic Oncology, 2000
- Back to the Future: Multiagent Chemotherapy in Ovarian Cancer RevisitedJournal of Clinical Oncology, 1999
- Phase I and Pharmacologic Study of the Combination of Paclitaxel, Cisplatin, and Topotecan Administered Intravenously Every 21 Days as First-Line Therapy in Patients With Advanced Ovarian CancerJournal of Clinical Oncology, 1999
- A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.Journal of Clinical Oncology, 1998
- Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.Journal of Clinical Oncology, 1998
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Cancer of the OvaryNew England Journal of Medicine, 1993